Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Expression Regulation, Neoplastic | 6 | 2017 | 1284 | 0.800 |
Why?
|
| Carcinoma, Lobular | 3 | 2017 | 81 | 0.770 |
Why?
|
| Lung Neoplasms | 7 | 2024 | 2360 | 0.760 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2010 | 1096 | 0.610 |
Why?
|
| Chromosome Aberrations | 2 | 2010 | 384 | 0.610 |
Why?
|
| Gene Silencing | 2 | 2016 | 178 | 0.540 |
Why?
|
| Cadherins | 2 | 2016 | 163 | 0.530 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 137 | 0.500 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2016 | 127 | 0.500 |
Why?
|
| Breast Neoplasms | 6 | 2023 | 3021 | 0.480 |
Why?
|
| Paracrine Communication | 1 | 2014 | 32 | 0.470 |
Why?
|
| Exosomes | 1 | 2014 | 53 | 0.450 |
Why?
|
| Gene Expression Profiling | 6 | 2016 | 1455 | 0.450 |
Why?
|
| Stromal Cells | 1 | 2014 | 151 | 0.440 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 606 | 0.410 |
Why?
|
| Bronchi | 2 | 2009 | 230 | 0.360 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 1124 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2010 | 109 | 0.350 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 538 | 0.320 |
Why?
|
| Respiratory Mucosa | 1 | 2009 | 88 | 0.310 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 693 | 0.310 |
Why?
|
| Genetic Markers | 1 | 2009 | 476 | 0.300 |
Why?
|
| Nucleic Acid Probes | 1 | 2007 | 1 | 0.290 |
Why?
|
| Poly A | 1 | 2007 | 23 | 0.290 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2007 | 40 | 0.290 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 496 | 0.280 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 264 | 0.280 |
Why?
|
| Mammary Glands, Human | 2 | 2017 | 24 | 0.280 |
Why?
|
| Neoplasms | 4 | 2023 | 3065 | 0.280 |
Why?
|
| Artifacts | 1 | 2007 | 246 | 0.250 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 166 | 0.250 |
Why?
|
| Smoking | 1 | 2009 | 625 | 0.240 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2024 | 7 | 0.240 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 1543 | 0.240 |
Why?
|
| Acrylamides | 1 | 2024 | 34 | 0.240 |
Why?
|
| Cell Line, Tumor | 5 | 2023 | 2588 | 0.240 |
Why?
|
| Aniline Compounds | 1 | 2024 | 59 | 0.230 |
Why?
|
| Whole Genome Sequencing | 2 | 2023 | 103 | 0.230 |
Why?
|
| Ascitic Fluid | 1 | 2024 | 38 | 0.230 |
Why?
|
| Genetic Counseling | 1 | 2023 | 102 | 0.210 |
Why?
|
| Thymidine Phosphorylase | 1 | 2003 | 5 | 0.210 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2024 | 83 | 0.210 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2023 | 37 | 0.200 |
Why?
|
| Peritoneal Neoplasms | 1 | 2024 | 181 | 0.200 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 86 | 0.200 |
Why?
|
| Neovascularization, Physiologic | 1 | 2003 | 143 | 0.200 |
Why?
|
| Mutation | 5 | 2024 | 4169 | 0.190 |
Why?
|
| ErbB Receptors | 1 | 2024 | 499 | 0.190 |
Why?
|
| Stomach Neoplasms | 1 | 2024 | 287 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 405 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 46 | 0.180 |
Why?
|
| Female | 14 | 2024 | 46620 | 0.180 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2023 | 169 | 0.170 |
Why?
|
| Genetic Therapy | 1 | 2003 | 372 | 0.170 |
Why?
|
| Gene Amplification | 3 | 2021 | 135 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 306 | 0.160 |
Why?
|
| Humans | 21 | 2024 | 90014 | 0.160 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 247 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 568 | 0.150 |
Why?
|
| Transcription Factor AP-2 | 1 | 2017 | 14 | 0.150 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2017 | 3 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 264 | 0.150 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 475 | 0.140 |
Why?
|
| Aged | 7 | 2024 | 19269 | 0.140 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 782 | 0.140 |
Why?
|
| Integrases | 1 | 2016 | 63 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 885 | 0.130 |
Why?
|
| Gene Editing | 1 | 2016 | 50 | 0.130 |
Why?
|
| Quinolines | 1 | 2016 | 86 | 0.130 |
Why?
|
| Signal Transduction | 3 | 2016 | 3406 | 0.130 |
Why?
|
| Imidazoles | 1 | 2016 | 140 | 0.130 |
Why?
|
| Animals | 8 | 2023 | 27551 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 268 | 0.120 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2014 | 26 | 0.120 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 53 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 394 | 0.120 |
Why?
|
| Interferons | 1 | 2014 | 127 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2014 | 126 | 0.110 |
Why?
|
| Cell Survival | 1 | 2016 | 983 | 0.110 |
Why?
|
| Microarray Analysis | 2 | 2011 | 95 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2014 | 173 | 0.110 |
Why?
|
| Middle Aged | 6 | 2024 | 26179 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 3682 | 0.110 |
Why?
|
| Physicians | 1 | 2020 | 692 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2016 | 1496 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 979 | 0.100 |
Why?
|
| Mice, Nude | 1 | 2014 | 816 | 0.100 |
Why?
|
| Male | 7 | 2024 | 42705 | 0.100 |
Why?
|
| Mice, Knockout | 1 | 2016 | 2017 | 0.090 |
Why?
|
| Phosphatidylethanolamine Binding Protein | 1 | 2011 | 38 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 6784 | 0.090 |
Why?
|
| Mice | 4 | 2023 | 11869 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2007 | 2026 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 2328 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 2503 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2014 | 1102 | 0.090 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 39 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2010 | 521 | 0.080 |
Why?
|
| Carcinogens | 1 | 2009 | 111 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 587 | 0.080 |
Why?
|
| Carcinoma | 1 | 2011 | 437 | 0.070 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 161 | 0.070 |
Why?
|
| Mitochondria | 1 | 2010 | 556 | 0.070 |
Why?
|
| Genomics | 2 | 2023 | 778 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2011 | 556 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2007 | 202 | 0.070 |
Why?
|
| Desmosomes | 1 | 2006 | 10 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 2009 | 258 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 88 | 0.060 |
Why?
|
| Integrins | 1 | 2006 | 78 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2006 | 303 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 1 | 2007 | 1048 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 313 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 133 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 1998 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1801 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2009 | 1869 | 0.060 |
Why?
|
| Peritoneal Lavage | 1 | 2024 | 12 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2024 | 66 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2017 | 1670 | 0.060 |
Why?
|
| Ascites | 1 | 2024 | 56 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2024 | 9239 | 0.060 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 48 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2024 | 266 | 0.050 |
Why?
|
| Workflow | 1 | 2023 | 81 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2006 | 726 | 0.050 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2023 | 5 | 0.050 |
Why?
|
| Umbilical Veins | 1 | 2003 | 46 | 0.050 |
Why?
|
| Thymine | 1 | 2003 | 17 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2023 | 36 | 0.050 |
Why?
|
| Indoles | 1 | 2024 | 301 | 0.050 |
Why?
|
| COS Cells | 1 | 2003 | 167 | 0.050 |
Why?
|
| Workload | 1 | 2023 | 129 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2003 | 103 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 2886 | 0.050 |
Why?
|
| Myofibroblasts | 1 | 2023 | 48 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2024 | 371 | 0.050 |
Why?
|
| Prognosis | 2 | 2024 | 3794 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2021 | 32 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2003 | 446 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2021 | 22 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2021 | 32 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 53 | 0.050 |
Why?
|
| Netherlands | 1 | 2020 | 24 | 0.050 |
Why?
|
| Transfection | 1 | 2003 | 909 | 0.050 |
Why?
|
| Carbamates | 1 | 2020 | 15 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 347 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 785 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 34 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 435 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2021 | 263 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 491 | 0.040 |
Why?
|
| Cetuximab | 1 | 2020 | 115 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 133 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2021 | 352 | 0.040 |
Why?
|
| Thiazoles | 1 | 2020 | 127 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 177 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 181 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2020 | 107 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2023 | 759 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 147 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2023 | 543 | 0.040 |
Why?
|
| Adult | 3 | 2024 | 26845 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2020 | 114 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 528 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 1183 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2020 | 320 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 280 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 204 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2003 | 2887 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 665 | 0.040 |
Why?
|
| Biomarkers | 1 | 2023 | 1779 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 422 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 376 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1731 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 841 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 375 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 154 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2016 | 83 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1169 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2769 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 2360 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 953 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 1579 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 2416 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2395 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 310 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 1065 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1766 | 0.010 |
Why?
|